{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,22]],"date-time":"2026-07-22T10:24:17Z","timestamp":1784715857921,"version":"3.55.0"},"reference-count":60,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2017,9,1]],"date-time":"2017-09-01T00:00:00Z","timestamp":1504224000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2017,5,24]],"date-time":"2017-05-24T00:00:00Z","timestamp":1495584000000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"funder":[{"DOI":"10.13039\/100015739","name":"Bayer Vital GmbH","doi-asserted-by":"crossref","id":[{"id":"10.13039\/100015739","id-type":"DOI","asserted-by":"crossref"}]}],"content-domain":{"domain":["clinicalkey.jp","clinicalkey.com","clinicalkey.es","clinicalkey.com.au","clinicalkey.fr","cancertreatmentreviews.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Cancer Treatment Reviews"],"published-print":{"date-parts":[[2017,9]]},"DOI":"10.1016\/j.ctrv.2017.04.007","type":"journal-article","created":{"date-parts":[[2017,5,4]],"date-time":"2017-05-04T18:30:24Z","timestamp":1493922624000},"page":"54-60","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":114,"special_numbering":"C","title":["Treatment decisions in metastatic colorectal cancer \u2013 Beyond first and second line combination therapies"],"prefix":"10.1016","volume":"59","author":[{"given":"A.","family":"Vogel","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"R.D.","family":"Hofheinz","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"S.","family":"Kubicka","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"D.","family":"Arnold","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.ctrv.2017.04.007_b0005","doi-asserted-by":"crossref","unstructured":"Venook AP, Niedzwiecki D, Lenz H-J, Innocenti F, Mahoney MR, O'Neil BH, et al. CALGB\/SWOG 80405: Phase III trial of irinotecan\/5-FU\/leucovorin (FOLFIRI) or oxaliplatin\/5-FU\/leucovorin (mFOLFOX6) with bevacizumab (BV) or cetuximab (CET) for patients (pts) with KRAS wild-type (wt) untreated metastatic adenocarcinoma of the colon or rectum (MCRC). American Society of Clinical Oncology (ASCO). Chicago, Illinois, USA: Journal of Clinical Oncology; 2014.","DOI":"10.1200\/jco.2014.32.18_suppl.lba3"},{"key":"10.1016\/j.ctrv.2017.04.007_b0010","doi-asserted-by":"crossref","first-page":"1065","DOI":"10.1016\/S1470-2045(14)70330-4","article-title":"FOLFIRI plus cetuximab versus FOLFIRI plus bevacizumab as first-line treatment for patients with metastatic colorectal cancer (FIRE-3): a randomised, open-label, phase 3 trial","volume":"15","author":"Heinemann","year":"2014","journal-title":"Lancet Oncol"},{"key":"10.1016\/j.ctrv.2017.04.007_b0015","doi-asserted-by":"crossref","first-page":"1306","DOI":"10.1016\/S1470-2045(15)00122-9","article-title":"FOLFOXIRI plus bevacizumab versus FOLFIRI plus bevacizumab as first-line treatment of patients with metastatic colorectal cancer: updated overall survival and molecular subgroup analyses of the open-label, phase 3 TRIBE study","volume":"16","author":"Cremolini","year":"2015","journal-title":"Lancet Oncol"},{"key":"10.1016\/j.ctrv.2017.04.007_b0020","doi-asserted-by":"crossref","unstructured":"Van Cutsem E, Cervantes A, Nordlinger B, Arnold D, Group EGW. Metastatic colorectal cancer: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up. Annals of Oncology: Official Journal of the European Society for Medical Oncology\/ESMO. 2014;25 Suppl 3:iii1-9.","DOI":"10.1093\/annonc\/mdu260"},{"key":"10.1016\/j.ctrv.2017.04.007_b0025","doi-asserted-by":"crossref","first-page":"1277","DOI":"10.1200\/JCO.2013.53.8009","article-title":"American Society of Clinical Oncology perspective: raising the bar for clinical trials by defining clinically meaningful outcomes","volume":"32","author":"Ellis","year":"2014","journal-title":"J Clin Oncol: Off J Am Soc Clin Oncol"},{"key":"10.1016\/j.ctrv.2017.04.007_b0030","doi-asserted-by":"crossref","first-page":"192","DOI":"10.1016\/S1470-2045(17)30006-2","article-title":"MABp1 as a novel antibody treatment for advanced colorectal cancer: a randomised, double-blind, placebo-controlled, phase 3 study","volume":"18","author":"Hickish","year":"2017","journal-title":"Lancet Oncol"},{"key":"10.1016\/j.ctrv.2017.04.007_b0035","doi-asserted-by":"crossref","first-page":"285","DOI":"10.1177\/030089160609200404","article-title":"Chemotherapy with mitomycin C and capecitabine in patients with advanced colorectal cancer pretreated with irinotecan and oxaliplatin","volume":"92","author":"Rimassa","year":"2006","journal-title":"Tumori"},{"key":"10.1016\/j.ctrv.2017.04.007_b0040","doi-asserted-by":"crossref","first-page":"820","DOI":"10.1016\/j.ejca.2012.01.008","article-title":"A multicenter, multinational analysis of mitomycin C in refractory metastatic colorectal cancer","volume":"48","author":"Ferrarotto","year":"2012","journal-title":"Eur J Cancer"},{"key":"10.1016\/j.ctrv.2017.04.007_b0045","doi-asserted-by":"crossref","first-page":"236","DOI":"10.1080\/02841860510029662","article-title":"Capecitabine as third line therapy in patients with advanced colorectal cancer","volume":"44","author":"Gubanski","year":"2005","journal-title":"Acta Oncol"},{"key":"10.1016\/j.ctrv.2017.04.007_b0050","first-page":"2971","article-title":"The efficacy of gemcitabine as salvage treatment in patients with refractory advanced colorectal cancer (CRC): a single institution experience","volume":"31","author":"Saif","year":"2011","journal-title":"Anticancer Res"},{"key":"10.1016\/j.ctrv.2017.04.007_b0055","first-page":"3055","article-title":"Gemcitabine and protracted 5-fluorouracil infusion as third-line chemotherapy in refractory colorectal cancer patients","volume":"28","author":"Bitossi","year":"2008","journal-title":"Anticancer Res"},{"key":"10.1016\/j.ctrv.2017.04.007_b0060","doi-asserted-by":"crossref","first-page":"384","DOI":"10.1007\/s12094-014-1243-1","article-title":"Gemcitabine plus capecitabine (Gem-Cape) biweekly in chemorefractory metastatic colorectal cancer","volume":"17","author":"Jimenez-Fonseca","year":"2015","journal-title":"Clin Translational Oncol: Off Publ Fed Spanish Oncol Soc Natl Cancer Inst Mexico"},{"key":"10.1016\/j.ctrv.2017.04.007_b0065","doi-asserted-by":"crossref","first-page":"1637","DOI":"10.1038\/sj.bjc.6603468","article-title":"A phase II trial of S-1 monotherapy in metastatic colorectal cancer after failure of irinotecan- and oxaliplatin-containing regimens","volume":"95","author":"Jeung","year":"2006","journal-title":"Br J Cancer"},{"key":"10.1016\/j.ctrv.2017.04.007_b0070","doi-asserted-by":"crossref","unstructured":"Sym SJ, Hong J, Ahn HJ, Park J, Cho EK, Lee WS, et al. A phase II trial of salvage treatment with gemcitabine and S-1 combination in heavily pretreated patients with metastatic colorectal cancer. American Society of Clinical Oncology (ASCO). Chicago, Illinois, USA: Journal of Clinical Oncology; 2013.","DOI":"10.1200\/jco.2013.31.4_suppl.488"},{"key":"10.1016\/j.ctrv.2017.04.007_b0075","doi-asserted-by":"crossref","first-page":"1757","DOI":"10.1056\/NEJMoa0804385","article-title":"K-ras mutations and benefit from cetuximab in advanced colorectal cancer","volume":"359","author":"Karapetis","year":"2008","journal-title":"N Engl J Med"},{"key":"10.1016\/j.ctrv.2017.04.007_b0080","doi-asserted-by":"crossref","first-page":"1626","DOI":"10.1200\/JCO.2007.14.7116","article-title":"Wild-type KRAS is required for panitumumab efficacy in patients with metastatic colorectal cancer","volume":"26","author":"Amado","year":"2008","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.ctrv.2017.04.007_b0085","doi-asserted-by":"crossref","first-page":"1206","DOI":"10.1038\/bjc.2016.309","article-title":"A phase 3 trial evaluating panitumumab plus best supportive care vs best supportive care in chemorefractory wild-type KRAS or RAS metastatic colorectal cancer","volume":"115","author":"Kim","year":"2016","journal-title":"Br J Cancer"},{"key":"10.1016\/j.ctrv.2017.04.007_b0090","doi-asserted-by":"crossref","first-page":"569","DOI":"10.1016\/S1470-2045(14)70118-4","article-title":"Panitumumab versus cetuximab in patients with chemotherapy-refractory wild-type KRAS exon 2 metastatic colorectal cancer (ASPECCT): a randomised, multicentre, open-label, non-inferiority phase 3 study","volume":"15","author":"Price","year":"2014","journal-title":"Lancet Oncol"},{"key":"10.1016\/j.ctrv.2017.04.007_b0095","doi-asserted-by":"crossref","first-page":"1405","DOI":"10.1016\/j.ejca.2015.03.015","article-title":"Location of colon cancer (right-sided versus left-sided) as a prognostic factor and a predictor of benefit from cetuximab in NCIC CO.17","volume":"51","author":"Brule","year":"2015","journal-title":"Eur J Cancer"},{"key":"10.1016\/j.ctrv.2017.04.007_b0100","doi-asserted-by":"crossref","first-page":"148","DOI":"10.1159\/000361031","article-title":"FOLFIRINOX bevacizumab is a promising therapy for chemorefractory metastatic colorectal cancer","volume":"87","author":"Chaix","year":"2014","journal-title":"Oncology"},{"key":"10.1016\/j.ctrv.2017.04.007_b0105","doi-asserted-by":"crossref","first-page":"601","DOI":"10.1186\/s12885-015-1606-1","article-title":"A single-arm phase II trial of combined chemotherapy with S-1, oral leucovorin, and bevacizumab in heavily pre-treated patients with metastatic colorectal cancer","volume":"15","author":"Yamaguchi","year":"2015","journal-title":"BMC Can"},{"key":"10.1016\/j.ctrv.2017.04.007_b0110","doi-asserted-by":"crossref","first-page":"1487","DOI":"10.1002\/ijc.28669","article-title":"Regorafenib (BAY 73\u20134506): antitumor and antimetastatic activities in preclinical models of colorectal cancer","volume":"135","author":"Schmieder","year":"2014","journal-title":"Int J Can J Int du Can"},{"key":"10.1016\/j.ctrv.2017.04.007_b0115","doi-asserted-by":"crossref","DOI":"10.1200\/jco.2015.33.3_suppl.710","article-title":"Subgroup analysis of patients with metastatic colorectal cancer (mCRC) treated with regorafenib (REG) in the CORRECT trial who had progression-free survival (PFS) longer than 4 months","volume":"33","author":"Grothey","year":"2015","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.ctrv.2017.04.007_b0120","doi-asserted-by":"crossref","first-page":"303","DOI":"10.1016\/S0140-6736(12)61900-X","article-title":"Regorafenib monotherapy for previously treated metastatic colorectal cancer (CORRECT): an international, multicentre, randomised, placebo-controlled, phase 3 trial","volume":"381","author":"Grothey","year":"2013","journal-title":"Lancet"},{"key":"10.1016\/j.ctrv.2017.04.007_b0125","first-page":"710","article-title":"Subgroup analysis of patients with metastatic colorectal cancer (mCRC) treated with regorafenib (REG) in the CORRECT trial who had progression-free survival (PFS) longer than 4 months","volume":"33","author":"Grothey","year":"2015","journal-title":"ASCO Meet Abstr"},{"key":"10.1016\/j.ctrv.2017.04.007_b9000","doi-asserted-by":"crossref","first-page":"e000111","DOI":"10.1136\/esmoopen-2016-000111","article-title":"Radiological imaging markers predicting clinical outcome in patients with metastatic colorectal carcinoma treated with regorafenib: post hoc analysis of the CORRECT phase III trial (RadioCORRECT study)","volume":"1","author":"Ricotta","year":"2017","journal-title":"ESMO Open"},{"key":"10.1016\/j.ctrv.2017.04.007_b0130","doi-asserted-by":"crossref","first-page":"619","DOI":"10.1016\/S1470-2045(15)70156-7","article-title":"Regorafenib plus best supportive care versus placebo plus best supportive care in Asian patients with previously treated metastatic colorectal cancer (CONCUR): a randomised, double-blind, placebo-controlled, phase 3 trial","volume":"16","author":"Li","year":"2015","journal-title":"Lancet Oncol"},{"key":"10.1016\/j.ctrv.2017.04.007_b0135","doi-asserted-by":"crossref","unstructured":"Tougeron D, de la Fouchardiere C, Etienne PL, Dourthe LM, Mineur L, Paule B, et al. REBECCA: A large cohort study of Regorafenib (REG) in the real-life setting in patients (pts) previously treatment for metastatic colorectal cancer (mCRC). European Society of Medical Oncology 2014. Madrid, Spain 2014.","DOI":"10.1093\/annonc\/mdu333.104"},{"key":"10.1016\/j.ctrv.2017.04.007_b0140","doi-asserted-by":"crossref","unstructured":"Van Cutsem E, Ciardiello F, Hofheinz R, Verma U, Garcia-Carbonero R, Grothey A, et al. Results from the large, open-label phase 3b CONSIGN study of regorafenib in patients with previously treated metastatic colorectal cancer. ESMO World Congress on Gastrointestinal Cancer 2015. Barcelona, Spain: Annals of Oncology; 2015. p. iv118.","DOI":"10.1093\/annonc\/mdv262.05"},{"key":"10.1016\/j.ctrv.2017.04.007_b0145","doi-asserted-by":"crossref","first-page":"1227","DOI":"10.1016\/S0006-2952(00)00253-7","article-title":"Structure and activity of specific inhibitors of thymidine phosphorylase to potentiate the function of antitumor 2'-deoxyribonucleosides","volume":"59","author":"Fukushima","year":"2000","journal-title":"Biochem Pharmacol"},{"key":"10.1016\/j.ctrv.2017.04.007_b0150","doi-asserted-by":"crossref","first-page":"993","DOI":"10.1016\/S1470-2045(12)70345-5","article-title":"TAS-102 monotherapy for pretreated metastatic colorectal cancer: a double-blind, randomised, placebo-controlled phase 2 trial","volume":"13","author":"Yoshino","year":"2012","journal-title":"Lancet Oncol"},{"key":"10.1016\/j.ctrv.2017.04.007_b0155","doi-asserted-by":"crossref","first-page":"467","DOI":"10.1186\/s12885-016-2491-y","article-title":"Chemotherapy induced neutropenia at 1-month mark is a predictor of overall survival in patients receiving TAS-102 for refractory metastatic colorectal cancer: a cohort study","volume":"16","author":"Kasi","year":"2016","journal-title":"BMC Can"},{"key":"10.1016\/j.ctrv.2017.04.007_b0160","doi-asserted-by":"crossref","DOI":"10.1093\/annonc\/mdw435.12","article-title":"Nintedanib plus best supportive care (BSC) versus placebo plus BSC for the treatment of patients (pts) with colorectal cancer (CRC) refractory to standard therapies: results of the phase III LUME-colon 1 study","volume":"27","author":"Van Cutsem","year":"2016","journal-title":"Ann Oncol"},{"key":"10.1016\/j.ctrv.2017.04.007_b0165","first-page":"513","article-title":"A randomized, double-blind, parallel-group, placebo-controlled, multicenter, phase II clinical study of famitinib in the treatment of advanced metastatic colorectal cancer","volume":"33","author":"R-h","year":"2015","journal-title":"ASCO Meet Abstr"},{"key":"10.1016\/j.ctrv.2017.04.007_b0170","doi-asserted-by":"crossref","first-page":"404","DOI":"10.1093\/annonc\/mdt547","article-title":"Activity of temozolomide in patients with advanced chemorefractory colorectal cancer and MGMT promoter methylation","volume":"25","author":"Pietrantonio","year":"2014","journal-title":"Ann Oncol: Off J Eur Soc Med Oncol\/ESMO"},{"key":"10.1016\/j.ctrv.2017.04.007_b0175","doi-asserted-by":"crossref","first-page":"508","DOI":"10.1158\/2159-8290.CD-11-0109","article-title":"A molecularly annotated platform of patient-derived xenografts (\u201cxenopatients\u201d) identifies HER2 as an effective therapeutic target in cetuximab-resistant colorectal cancer","volume":"1","author":"Bertotti","year":"2011","journal-title":"Cancer Discov"},{"key":"10.1016\/j.ctrv.2017.04.007_b0180","doi-asserted-by":"crossref","first-page":"738","DOI":"10.1016\/S1470-2045(16)00150-9","article-title":"Dual-targeted therapy with trastuzumab and lapatinib in treatment-refractory, KRAS codon 12\/13 wild-type, HER2-positive metastatic colorectal cancer (HERACLES): a proof-of-concept, multicentre, open-label, phase 2 trial","volume":"17","author":"Sartore-Bianchi","year":"2016","journal-title":"Lancet Oncol"},{"key":"10.1016\/j.ctrv.2017.04.007_b0185","doi-asserted-by":"crossref","DOI":"10.1200\/jco.2016.34.4_suppl.653","article-title":"Targeted therapy for gastrointestinaI (GI) tumors based on molecular profiles: early results from MyPathway, an open-label phase IIa basket study in patients with advanced solid tumors","volume":"34","author":"Hurwitz","year":"2016","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.ctrv.2017.04.007_b0190","doi-asserted-by":"crossref","first-page":"4032","DOI":"10.1200\/JCO.2015.63.2497","article-title":"Phase II pilot study of vemurafenib in patients with metastatic BRAF-mutated colorectal cancer","volume":"33","author":"Kopetz","year":"2015","journal-title":"J Clin Oncol: Offi J Am Soc Clin Oncol"},{"key":"10.1016\/j.ctrv.2017.04.007_b0195","doi-asserted-by":"crossref","first-page":"1352","DOI":"10.1158\/2159-8290.CD-16-0050","article-title":"Phase IB study of vemurafenib in combination with irinotecan and cetuximab in patients with metastatic colorectal cancer with BRAFV600E mutation","volume":"6","author":"Hong","year":"2016","journal-title":"Cancer Discov"},{"key":"10.1016\/j.ctrv.2017.04.007_b0200","doi-asserted-by":"crossref","first-page":"127","DOI":"10.1093\/annonc\/mdw198.25","article-title":"Combination of encorafenib and cetuximab with or without alpelisib in patients with advanced BRAF-mutant colorectal cancer (BRAFm CRC): phase 2 results","volume":"27","author":"Tabernero","year":"2016","journal-title":"Ann Oncol"},{"key":"10.1016\/j.ctrv.2017.04.007_b0205","doi-asserted-by":"crossref","DOI":"10.1093\/annonc\/mdw370.04","article-title":"Efficacy and circulating tumor DNA (ctDNA) analysis of the BRAF inhibitor dabrafenib (D), MEK inhibitor trametinib (T), and anti-EGFR antibody panitumumab (P) in patients (pts) with BRAF V600E\u2013mutated (BRAFm) metastatic colorectal cancer (mCRC)","volume":"27","author":"Corcoran","year":"2016","journal-title":"Ann Oncol"},{"key":"10.1016\/j.ctrv.2017.04.007_b0210","doi-asserted-by":"crossref","first-page":"2509","DOI":"10.1056\/NEJMoa1500596","article-title":"PD-1 blockade in tumors with mismatch-repair deficiency","volume":"372","author":"Le","year":"2015","journal-title":"N Engl J Med"},{"key":"10.1016\/j.ctrv.2017.04.007_b0215","unstructured":"Merck. Merck Receives Breakthrough Therapy Designation from U.S. Food and Drug Administration for KEYTRUDA\u00ae (pembrolizumab) in Advanced Colorectal Cancer; 2015. p. Press release."},{"key":"10.1016\/j.ctrv.2017.04.007_b0220","doi-asserted-by":"crossref","DOI":"10.1200\/JCO.2016.34.15_suppl.3501","article-title":"Nivolumab \u00b1 ipilimumab in treatment (tx) of patients (pts) with metastatic colorectal cancer (mCRC) with and without high microsatellite instability (MSI-H): CheckMate-142 interim results","volume":"34","author":"Overman","year":"2016","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.ctrv.2017.04.007_b0225","doi-asserted-by":"crossref","first-page":"1350","DOI":"10.1038\/nm.3967","article-title":"The consensus molecular subtypes of colorectal cancer","volume":"21","author":"Guinney","year":"2015","journal-title":"Nat Med"},{"key":"10.1016\/j.ctrv.2017.04.007_b0230","doi-asserted-by":"crossref","first-page":"79","DOI":"10.1038\/nrc.2016.126","article-title":"Consensus molecular subtypes and the evolution of precision medicine in colorectal cancer","volume":"17","author":"Dienstmann","year":"2017","journal-title":"Nat Rev Cancer"},{"key":"10.1016\/j.ctrv.2017.04.007_b0235","doi-asserted-by":"crossref","unstructured":"Teufel M, Schwenke S, Seidel H, Beckmann G, Reischl J, Vonk R, et al. Molecular subtypes and outcomes in regorafenib-treated patients with metastatic colorectal cancer (mCRC) enrolled in the CORRECT trial. ASCO 2015. Chicago, Illinois, USA; 2015.","DOI":"10.1200\/jco.2015.33.15_suppl.3558"},{"key":"10.1016\/j.ctrv.2017.04.007_b0240","doi-asserted-by":"crossref","first-page":"92","DOI":"10.1186\/1756-9966-32-92","article-title":"Rechallenge therapy and treatment holiday: different strategies in management of metastatic colorectal cancer","volume":"32","author":"Tonini","year":"2013","journal-title":"J Exp Clin Can Res: CR"},{"key":"10.1016\/j.ctrv.2017.04.007_b0245","first-page":"500","article-title":"Outcomes in patients (pts) with colorectal cancer (CRC) treated with oxaliplatin-based chemotherapy (OC) following prior oxaliplatin exposure","volume":"31","author":"Bhadkamkar","year":"2013","journal-title":"ASCO Meet Abst"},{"key":"10.1016\/j.ctrv.2017.04.007_b0250","doi-asserted-by":"crossref","first-page":"49","DOI":"10.1097\/COC.0b013e31823fe40e","article-title":"Rechallenge with oxaliplatin and fluoropyrimidine for metastatic colorectal carcinoma after prior therapy","volume":"36","author":"Townsend","year":"2013","journal-title":"Am J Clin Oncol"},{"key":"10.1016\/j.ctrv.2017.04.007_b0255","doi-asserted-by":"crossref","first-page":"3813","DOI":"10.1016\/j.ejca.2013.07.150","article-title":"Platinum-sensitivity in metastatic colorectal cancer: towards a definition","volume":"49","author":"Chibaudel","year":"2013","journal-title":"Eur J Cancer"},{"key":"10.1016\/j.ctrv.2017.04.007_b0260","first-page":"e14511","article-title":"Efficacy and saftey of capecitabine, oxaliplatin, and irinotecan (xeloxiri) as salvage therapy for patients with treatment-refractory metastatic colorectal cancer: a prospective, open-label, phase II study. ASCO","volume":"32","author":"Yau","year":"2014","journal-title":"Meet Abstr"},{"key":"10.1016\/j.ctrv.2017.04.007_b0265","doi-asserted-by":"crossref","first-page":"2157","DOI":"10.1158\/1078-0432.CCR-14-2821","article-title":"Emergence of multiple EGFR extracellular mutations during cetuximab treatment in colorectal cancer","volume":"21","author":"Arena","year":"2015","journal-title":"Clin Cancer Res"},{"key":"10.1016\/j.ctrv.2017.04.007_b0270","doi-asserted-by":"crossref","first-page":"827","DOI":"10.1038\/nm0715-827b","article-title":"Clonal evolution and resistance to EGFR blockade in the blood of colorectal cancer patients","volume":"21","author":"Siravegna","year":"2015","journal-title":"Nat Med"},{"key":"10.1016\/j.ctrv.2017.04.007_b0275","doi-asserted-by":"crossref","first-page":"1386","DOI":"10.1093\/annonc\/mdw235","article-title":"ESMO consensus guidelines for the management of patients with metastatic colorectal cancer","volume":"27","author":"Van Cutsem","year":"2016","journal-title":"Ann Oncol: Off J Eur Soc Med Oncol\/ESMO"},{"key":"10.1016\/j.ctrv.2017.04.007_b0280","unstructured":"Network NCC."},{"key":"10.1016\/j.ctrv.2017.04.007_b0285","doi-asserted-by":"crossref","first-page":"1909","DOI":"10.1056\/NEJMoa1414325","article-title":"Randomized trial of TAS-102 for refractory metastatic colorectal cancer","volume":"372","author":"Mayer","year":"2015","journal-title":"N Engl J Med"},{"key":"10.1016\/j.ctrv.2017.04.007_b0290","doi-asserted-by":"crossref","first-page":"2040","DOI":"10.1056\/NEJMoa071834","article-title":"Cetuximab for the treatment of colorectal cancer","volume":"357","author":"Jonker","year":"2007","journal-title":"New Engl J Med"},{"key":"10.1016\/j.ctrv.2017.04.007_b0295","doi-asserted-by":"crossref","first-page":"1658","DOI":"10.1200\/JCO.2006.08.1620","article-title":"Open-label phase III trial of panitumumab plus best supportive care compared with best supportive care alone in patients with chemotherapy-refractory metastatic colorectal cancer","volume":"25","author":"Van Cutsem","year":"2007","journal-title":"J Clin Oncol: Offic J Am Soc Clin Oncol"}],"container-title":["Cancer Treatment Reviews"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0305737217300658?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0305737217300658?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2020,5,17]],"date-time":"2020-05-17T21:30:40Z","timestamp":1589751040000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0305737217300658"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2017,9]]},"references-count":60,"alternative-id":["S0305737217300658"],"URL":"https:\/\/doi.org\/10.1016\/j.ctrv.2017.04.007","relation":{},"ISSN":["0305-7372"],"issn-type":[{"value":"0305-7372","type":"print"}],"subject":[],"published":{"date-parts":[[2017,9]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Treatment decisions in metastatic colorectal cancer \u2013 Beyond first and second line combination therapies","name":"articletitle","label":"Article Title"},{"value":"Cancer Treatment Reviews","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.ctrv.2017.04.007","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2017 The Authors. Published by Elsevier Ltd.","name":"copyright","label":"Copyright"}]}}